Pharmaceutical & Healthcare Research Report

Breaking

Showing posts with label Telangiectasias Therapeutics. Show all posts
Showing posts with label Telangiectasias Therapeutics. Show all posts

Friday, April 26, 2019

April 26, 2019

Telangiectasias Therapeutics- Pipeline Analysis 2018


Telangiectasias are dilated blood vessels located near the surface of skin or mucous membranes. These often appear as fine pink or red lines, which temporarily whiten under pressure. Although this disease can be developed in healthy individuals, telangiectasias is known to be a prime feature of systemic and limited scleroderma and dermatomyositis. 



Telangiectasias may occur in rosacea, in certain systemic diseases (such as ataxia-telangiectasia, scleroderma), or in long-term therapy with topical fluorinated corticosteroids. 
 
For more information get the sample report at:
https://www.pharmaproff.com/report/telangiectasis-therapeutics-pipeline-analysis


Spider telangiectases, costal fringe, generalised essential telangiectasia, hereditary haemorrhagic telangiectasia, angioma serpiginosum, unilateral naevoid telangiectasia and poikilodermatous mycoses fungoides are some types of primary telangiectases. Although most telangiectases are self-limiting, for cosmetically sensitive areas of the body, gentle cautery can be used for small numbers of lesions.